Jill Becher spent more than three years in agonizing pain. After one surgery failed, a riskier treatment provided relief.

Research study could lead to new therapies for people who suffer nerve injuries following auto accidents, gunshots.

MIRA Pharmaceuticals stock rises as new preclinical data reveal its oral ketamine analog Ketamir-2 is 60% more effective than ...

A collaborative study in neuroscience, spearheaded by a research team of the Hong Kong University of Science and Technology ...

Insect venom may seem like an unlikely ally in the discovery of new human pain treatments, but the latest findings into the ...

Realizing a Phase I human clinical trial commencing to test the efficacy and safety of the transplantation of olfactory cell nerve bridges to treat chronic spinal cord injury.

From the feedback in numerous Nerve Restore reviews, it’s apparent that this focus on the myelin sheath has offered many a new lease on life, free from the debilitating effects of nerve damage.

As we start looking to the year ahead, the pharma industry is gearing up for a slate of new drug launches and U.S. Food and ...

Autonomix Medical, Inc. (NASDAQ:AMIX) stock is trading higher on Monday, with a strong session volume of 6.11 million ...

According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic ...

Recent evidence suggests that acupuncture can help relieve the pain caused by sciatica, a common condition in which the ...

Promising Preclinical Results Position Ketamir-2 as a Potential Breakthrough Therapy That Surpasses Current Treatments, With Results to Be ...